Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its self-developed Category 1 innovative drug, Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody-drug conjugate (ADC), has received NMPA approval for a new indication in HER2-positive breast cancer – marking the second approved indication for the independently developed ADC and expanding its addressable market beyond the initial HER2-mutant NSCLC approval.
Differentiated payload/linker vs. T-DXd; potential efficacy/safety differentiation in head-to-head studies
Hengrui ADC Strategy
SHR-A1811 lead asset in HER2 ADC franchise; pipeline includes HER2-low, TROP2, CLDN18.2 ADCs
Multi-indication HER2 platform validation supports broader ADC portfolio development
Market Impact & Outlook
HER2 ADC Market Dynamics: Global HER2 ADC market exceeds US$10 billion annually; China represents 20-25% of volume with DS-8201 (Enhertu) capturing 60%+ share in post-HER2 therapy setting; SHR-A1811’s second indication positions for 15-20% market share in China HER2+ breast cancer (2027-2030).
Revenue Trajectory: Assuming RMB800 million-1.2 billion annual peak sales across both indications (2028-2030); breast cancer indication likely 70%+ of volume given larger patient population vs. HER2-mutant NSCLC niche; NRDL inclusion (negotiated 2025-2026) critical for volume scaling.
Clinical Expansion Pipeline: Potential for earlier-line breast cancer (first-line HER2+ in combination with pertuzumab), HER2-low breast cancer (following DS-8201 label expansion), and gastric cancer (HER2+ GC indication under development); global Phase III studies may support ex-China partnerships.
Hengrui Innovation Validation: Second indication approval within 10 months of initial nod demonstrates regulatory execution capabilities and clinical data quality; self-developed ADC platform (vs. in-licensing) supports sustainable competitive advantage and margin structure.
Competitive Response: DS-8201’s efficacy benchmark (DESTINY-Breast03: 75.8% ORR, 25.1 mo PFS) sets high bar; SHR-A1811’s real-world performance and head-to-head data (if conducted) will determine market share capture vs. premium-priced Enhertu and emerging domestic competitors (RemeGen, ADC Therapeutics China).
Forward-Looking Statements This brief contains forward-looking statements regarding commercialization expectations, market share projections, and pipeline expansion timelines for SHR-A1811. Actual results may differ due to competitive dynamics with DS-8201, reimbursement negotiations, and clinical performance in real-world settings.-Fineline Info & Tech
By Fineline Cube